international partnership for microbicides new science, new hope: giving women power over aids the...
TRANSCRIPT
International Partnership for MicrobicidesInternational Partnership for Microbicides
New Science, New Hope: Giving Women Power Over AIDS
The John Kevany Memorial Lecture
Zeda Rosenberg, ScD, Chief Executive Officer
NUI Maynooth, 29 November 2010
The Challenge of HIV/AIDS
People Living with HIV in 2009People Living with HIV in 2009
Total: 33.3 million UNAIDS/WHO 2010
Western & Central Europe
820 000Middle East & North Africa
460 000Sub-Saharan Africa
22.5 million
Eastern Europe & Central Asia
1.4 million
South & South-East Asia
4.1 millionOceania
57 000
North America
1.5 million
Latin America
1.4 million
East Asia
770 000Caribbean
240 000
Women’s Vulnerability to HIVWomen’s Vulnerability to HIV
Biological, economic and socio-cultural factors:
• Male-to-female transmission higher• Young women at even greater risk• Financial dependence on male partners• Inequality of women (exploitation and
violence)• Cultural practices such as early marriages,
intergenerational sex and concurrent partnerships
The Face of HIV/AIDS in AfricaThe Face of HIV/AIDS in Africa
Female 60% in sub-Saharan Africa
Young 3-5 times more likely to
become infected
Married and monogamous Stable relationships not
a haven
A mother Pregnancy complicated
by HIVWorld Bank Photo
HIV Prevention – The Global Response
From AIDS Treatment to HIV PreventionFrom AIDS Treatment to HIV Prevention
1981
1983
19871997
First AIDS case reported in the US
HIV virus identified
ARV “one drug” mono-therapy approved for use
Three-drug therapy: HAART.
30+ approved drugs for treatment: research continues
2002
Global Fund established
2003
Drug combinations/ reducing pill burden
20062010
ARVs in gel and pill effective for HIV prevention
PEPFAR launched
Prevention
Behavior change
Male and female condoms
STI treatment
Male circumcision
HIV vaccines
Prevention of mother to child transmission
Post-exposure prophylaxis (PEP)
Pre-exposure prophylaxis (PrEP)
Microbicides
ARV treatment
Treatment for opportunistic infections
Basic care
Current and Potential HIV/AIDS InterventionsCurrent and Potential HIV/AIDS Interventions
Treatmentand Care
Prevention
ARV-based:Non-ARV:
Promise of ARV-Based PrEPPromise of ARV-Based PrEP
Proof-of-concept for Truvada® Appropriate for men and
women Uses approved ARV drugs Convenient dosing: oral Potential for different dosing
strategies Intermittent dosing Monthly injection
Can combine more than one ARV in a single product
iPrEx: First Proof-of-Concept for PrEPiPrEx: First Proof-of-Concept for PrEP
First efficacy trial of ARV-based pre-exposure prophylaxis (PrEP) for HIV prevention
• Phase III: daily oral Truvada®• Two ARV drugs in one tablet: TDF and FTC• 2,499 MSM at 11 sites in Brazil, Ecuador, Peru, South
Africa, Thailand and the U.S.
First PrEP “proof-of-concept”• 44% protection against HIV• 73% protection in volunteers who took
study medication 90% or more of days• Safe, well-tolerated as tested
PrEP trials in other populations underway
Promise of ARV-based MicrobicidesPromise of ARV-based Microbicides
Antiretroviral (ARV)-based microbicides:
Target HIV specifically
Based on the same types of drugs successfully used to treat HIV and prevent mother to child transmission
Can be delivered in a variety of user-friendly forms: vaginal gel, ring, film, others
Potential to be developed as combination products
Proof of concept: tenofovir gel
CAPRISA 004 TrialCAPRISA 004 Trial
First efficacy trial of an ARV-based microbicide• Tenofovir gel (results July 2010)
First microbicide trial to show “proof of concept” • 889 women in South Africa
• Gel used within 12 hours before and after sex
• 39% protection against HIV
• 51% protection against HSV-2
• Gel safe as tested & no drug resistance detected
VOICE trial ongoing; additional study(ies) planned to start in 2011
Microbicide Development
What are Microbicides?What are Microbicides?
Topical products used to prevent HIV transmission to women
Could be delivered in many forms:
Ideally safe, effective, low cost, user friendly
Vaginal gel applicator
Long-acting vaginal ring
Vaginal tablet, soft gel capsule, film
Microbicide Development ProcessMicrobicide Development Process
• Research center staff,
infrastructure, training
• Community engagement
• HIV incidence studies
• Safety
• Efficacy
• Acceptability
• Clinical trials
• Licensure
• Post-licensure
studies
• Manufacturing
• Service delivery
• Availability
Research &
DevelopmentCapacity Building Clinical
Trials
Regulatory Approval
Launch & Access
Drug development approach consistent with regulatory path
• Intellectual
property rights
• Formulations
• Preclinical
studies
IPM’s Mission
Nonprofit product development partnership (PDP)
Offices in the United States, South Africa, Europe
IPM’s mission is to prevent HIV transmission by supporting the development and availability of safe and effective microbicides and other HIV prevention tools for use by women in developing countries
Partnerships With IndustryPartnerships With Industry
Non-exclusive, royalty-free licenses to develop, manufacture and
distribute compounds as microbicides in developing countries
Compound License Year Mechanism of Action
Dapivirine Tibotec 2004 Reverse transcription: Stops virus from copying its genetic material inside human cells
DS001 (L-860,167)DS004 (L-860,872)DS005 (L-860,882)
Merck2005 Cell Attachment: Prevents virus from attaching
to human cells
DS003 (BMS-599793) BMS 2005 Cell Attachment
Tenofovir(IPM & CONRAD) Gilead
2006 Reverse transcription
Maraviroc Pfizer 2008 Cell Attachment
DS007 (L-000889644) Merck 2008 Cell Fusion: Prevents virus from entering human cells
Microbicides in Product DevelopmentMicrobicides in Product Development
Free virus
Attachment
Fusion
ReverseTranscription
Protein synthesisand assembly
Budding
Maturation
Integration
Maraviroc
BMS 793L167, L872, L882
Tenofovir
Dapivirine
MIV-150
MIV-170
Pyrimidinediones
L’644 peptide
Need for Multiple Products & FormulationsNeed for Multiple Products & Formulations
Different women, different preferences
More product choices, more options for protection
Impact of adherence on efficacy - product won’t help if women don’t use it
Male partners’ opinions and preferences important
Vaginal Rings: An Attractive TechnologyVaginal Rings: An Attractive Technology
Long-acting
Easy to use• Flexible ring, can be self-inserted
Suitable for developing world• Heat-stable
Used safely for other purposes• Contraceptive and hormone
therapy rings
Suitable for drug combinations Dapivirine ring Phase III
planned in 2011
IPM PartnershipsIPM Partnerships
Multilaterals
Local communities
Private sector
Governments
Pharma
Civil society
Research Centers
Developers, Researchers
Regulatory bodies
IPM
IPM’s Research Studies Across the GlobeIPM’s Research Studies Across the Globe
Clinical Research Centers in AfricaClinical Research Centers in Africa
More than 10 local partners in 6 countries conduct research studies on behalf of IPM
Be Part Yoluntu
Centre
Capacity Building at Research CentersCapacity Building at Research Centers
Community engagement Referral networks for medical care,
treatment, support
Infrastructure and equipment
Staff training and development
Communications, messaging, tools
Financial management support
HIV incidence studies
Projet Ubuzima, Kigali, RwandaProjet Ubuzima, Kigali, Rwanda
HIV incidence studies and microbicide gel trial completed
Microbicide gel trial ongoing
Microbicide ring trial planned
Ladysmith, KwaZulu-Natal, South AfricaLadysmith, KwaZulu-Natal, South Africa
HIV incidence study completedMicrobicide ring & gel trials ongoing
Site selection & renovation Staff selection & training
Benefiting People, Communities, CountriesBenefiting People, Communities, Countries
Promote reproductive health and HIV awareness
Empower women through education and counselling
Involve men in HIV prevention
Encourage HIV testing
Strengthen delivery of and access to health services
Engage communities, build community advisory (CAB)
Provide employment and professional development
Building medical research capabilities in geographical areas of need
Access Access
Access Principles: Planning for SuccessAccess Principles: Planning for Success
Availability
Accessibility
Acceptability
Affordability
Acceptability Studies in AfricaVaginal ring, film, tablet, soft gel capsule
Acceptability Studies in AfricaVaginal ring, film, tablet, soft gel capsule
All formulations acceptable
Different formulations preferred in different countries
Women very likely to use all products to prevent HIV
Interest in discreet use
Access: Preparing for SuccessAccess: Preparing for Success
IPM Access Strategy
Intellectual property agreements evolution• Pfizer, Merck 2008, Tibotec
Acceptability/market research studies• IPM 011, PAS 2
Global manufacturing survey completed
LSHTM modeling of microbicide introduction
Pharma lessons learned ARV treatment intro
Annual Microbicide Access Forum
Key Regulatory Aspects of AccessKey Regulatory Aspects of Access
Demonstration of efficacy in Phase III trial does not automatically translate into product licensure or immediate access to product
Regulatory licensure requires review for:• Product quality (CMC)• Safety (preclinical and clinical)• Efficacy
However, very limited access to product can be achieved through clinical programs
Empowering Women Empowering Women
Women’s Right to Health Women’s Right to Health
Human right to health in many UN rights treaties
Women’s right to health in • ICPD Programme of Action (1994)• The Beijing Platform for Action (1995)
Women’s productivity and humanity undermined without high standard of health
HIV protection responds to woman’s risks of infection
Microbicides could provide a vital HIV prevention tool for women and enable them to protect their health
and that of their families
Microbicides and the Millennium Development Goals
Microbicides and the Millennium Development Goals
Microbicides have the potential to impact
7 of 8 MDGs
Source: United Nations
Concluding RemarksConcluding Remarks
Ireland – Pioneering Support Ireland – Pioneering Support
IPM thanks the people of Ireland and the Irish Government and for your unwavering commitment to microbicide development and the needs of women in the developing world.
Women Urgently Need MicrobicidesWomen Urgently Need Microbicides
“A microbicide could mean the difference between life
and death for millions of women. Let us do everything
in our power to accelerate its development.”
Mrs. Graça Machel
THANK YOU!THANK YOU!